Kyle Diamantas has held the acting FDA commissioner role since Marty Makary’s May 2026 resignation, giving him an edge through demonstrated leadership of the Human Foods Program and internal continuity. Competing names such as Brett Giroir and Stephen Hahn draw from prior Trump administration experience, while Sara Brenner and Grace Graham represent other regulatory backgrounds under consideration. Senate confirmation requirements and ongoing White House vetting have extended the process, supporting elevated odds on no formal announcement by year-end. Recent performance reports on Diamantas and shifting finalist lists keep the field competitive without a clear frontrunner emerging.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · ОбновленоКайл Диамантис 13%
Бретт Жируар 8.2%
Сара Бреннер 7.2%
Стивен Хан 6.2%
$18,953 Объем
$18,953 Объем
Кайл Диамантис
26%
Стивен Хан
6%
Бретт Жируар
8%
Грейс Грэм
4%
Сара Бреннер
7%
Нет объявления до 31 декабря
33%
Кайл Диамантис 13%
Бретт Жируар 8.2%
Сара Бреннер 7.2%
Стивен Хан 6.2%
$18,953 Объем
$18,953 Объем
Кайл Диамантис
26%
Стивен Хан
6%
Бретт Жируар
8%
Грейс Грэм
4%
Сара Бреннер
7%
Нет объявления до 31 декабря
33%
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Открытие рынка: May 12, 2026, 7:59 PM ET
Resolver
0x69c47De9D...An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Resolver
0x69c47De9D...Kyle Diamantas has held the acting FDA commissioner role since Marty Makary’s May 2026 resignation, giving him an edge through demonstrated leadership of the Human Foods Program and internal continuity. Competing names such as Brett Giroir and Stephen Hahn draw from prior Trump administration experience, while Sara Brenner and Grace Graham represent other regulatory backgrounds under consideration. Senate confirmation requirements and ongoing White House vetting have extended the process, supporting elevated odds on no formal announcement by year-end. Recent performance reports on Diamantas and shifting finalist lists keep the field competitive without a clear frontrunner emerging.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · Обновлено


Не доверяй внешним ссылкам.
Не доверяй внешним ссылкам.
Часто задаваемые вопросы